TruDiagnostic Most biomarkers tell you where a patient is right now. DNA methylation tells you where they’re headed and why. TruDiagnostic is a CLIA-certified epigenetics lab and research partner specializing in DNA methylation analysis for biological age, disease risk, and multi-system health performance. Founded in 2020, we’ve built one of the largest private methylation datasets in the world: 200,000+ participants, 80+ published studies, and 115+ active research collaborators – including institutions publishing in Nature Aging and peer-reviewed clinical journals. Our positioning is deliberate: science over commercialization. Every product we offer is grounded in rigorous, independently validated research. What we bring to the table for our partners: Our Epigenetic Biomarker Proxies (EBPs) predict 2,000+ protein and metabolite biomarkers directly from a blood spot. In head-to-head comparisons, these DNA Methylation derived biomarkers outperform traditional direct measurements 62% of the time, with better effect sizes and greater signal stability. Unlike point-in-time assays, methylation patterns reflect long-term biological averages, making them less susceptible to day-to-day biological noise. Our Methylation Risk Scores (MRS) predict 5- and 10-year disease risk with ~90% accuracy across cardiovascular disease, diabetes, Alzheimer’s, Parkinson’s, and cognitive decline. Unlike polygenic risk scores, MRS are modifiable — they respond to interventions, making them uniquely actionable for clinical trials, therapeutic validation, and personalized medicine applications. Our immune deconvolution platform reconstructs cell-type composition from whole blood with only a 3% error rate compared to flow cytometry, at a fraction of the cost and complexity. We collaborate across pharma, consumer health, and clinical research. Deliverables include processed IDAT files and beta values, custom aging clocks, organ-specific risk scores, cohort-level analysis reports, and intervention efficacy assessments. Our work with Olaplex on tissue-specific skin aging demonstrates how this technology extends well beyond blood. If you’re running clinical trials, building risk stratification tools, or looking for a methylation data partner with the depth to support real discovery, we’re built for that conversation.
Trinzz
Trinzz builds the foundational data layer for medical AI. We create clinical-grade, regulatory-ready datasets through expert-led annotation workflows and multi-layer quality control across multimodal imaging. By combining domain specialists with structured validation pipelines, we enable healthcare AI teams to move from training environments to real-world clinical deployment with confidence.
Tri-Imaging Solutions
Tri-Imaging Solutions is a trusted global partner in the diagnostic imaging industry, delivering innovative imaging parts, equipment solutions, technology-driven service support, and state-of-the-art training. Following the strategic integration of DirectMed Imaging, our combined organization brings expanded inventory, deeper technical expertise, and enhanced support capabilities to healthcare providers. With a growing footprint and multiple distribution hubs, we provide fast, reliable access to critical components while equipping in-house teams with the tools and expertise needed to improve efficiency and reduce costs. Our mission is simple: to strengthen healthcare organizations through smarter, more strategic imaging solutions.
TransGen Biotech Co., Ltd
TransGen Biotech Co., Ltd is a leading supplier of laboratory reagents and instruments focusing on molecular biology, cell biology and immunology since 2006. With expertise in scientific research, we provides more than 200 self-developed and world-recognized products covering upstream to downstream of life sciences and biotech industry (ISO 9001 and ISO13285 obtained).
Transcend
Transcend is the data permissioning layer that unlocks health data activation, AI, and monetization at scale. While fragmented permissions across EHRs and portals often bottleneck innovation, Transcend centralizes patient consent into a unified source of truth. We replace disconnected workflows with real-time enforcement across your entire tech stack, ensuring compliance is an enabler rather than a blocker. By bridging the gap between data silos and action, Transcend empowers health systems to: – Personalize outreach and engagement. – Accelerate AI initiatives safely. – Unlock new revenue streams through secure data monetization. Drive better outcomes with data that is finally usable. | Transcend is the compliance layer for patient data, enabling healthcare organizations to activate AI and data-driven initiatives responsibly and at scale. Health systems and healthcare innovators rely on Transcend to embed HIPAA-compliant governance and privacy controls directly into their technology stacks. By replacing manual, fragmented workflows with a unified, system-level layer, Transcend enforces data permissions in real-time across patient data stores, cloud platforms, and AI systems.
TOYOBO USA
In the 1950s, TOYOBO began investigating microorganisms for treating waste water from one of our plants that processed pulp for rayon. Scientists in our laboratories discovered that a certain type of yeast was consuming sugar in the waste water, substantially reducing the biochemical oxygen demand (BOD) level. We then filtered out the yeast to market it for animal food. As the proportion of nucleic acids in the yeast was extremely high, we separated them out and did research for use in food seasonings. In the 1960s, based on a success in commercializing uricase from Candida sp., the first of its kind, we expanded our focus to include the field of clinical chemistry. Now TOYOBO excels in the market with more than 60 kinds of material enzymes for diagnostic reagents. We also provide many kinds of materials and kits for research use at the forefront of the field of molecular biology. TOYOBO Healthcare products are renowned both in Japan and around the world for the finest level of quality on the market.
TLC BioSciences
TLC BioSciences is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD®). TLC’s deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX® active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC was consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations every year until the company went private in 2021. | TLC BioSciences is a late clinical stage specialty pharmaceutical company. At TLC, we are dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management. | TLC is dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management. | TLC BioSciences is a clinical‑stage biotechnology company advancing lipid‑engineered medicines across metabolic, orthopedic, and immune‑cell therapy. Our proprietary LipAD® family of platforms—including BioSeizer® sustained‑release technology, NanoX® active drug‑loading systems, and next‑generation targeted lipid nanoparticles (tLNP)—enables long‑acting, targeted, and programmable delivery for a wide range of therapeutic modalities. With a robust pipeline spanning once‑monthly GLP‑1 therapy (TLC518), late‑stage non‑opioid pain programs, and in‑vivo CAR‑T applications, TLC is committed to delivering medicines with improved efficacy, safety, and accessibility.